Logo

Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma

Share this

Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma

Shots:

  • The real-world data involves assessing of Spiriva Respima Inhalation Spray 1.25mcg + combination inhaled corticosteroid and long-acting beta2-agonist (ICS+LABA) vs increased dose of ICS+LABA or continuing high dose of ICS+LABA in patients with asthma
  • The study resulted in 73% lower exacerbation rates and 76% lower hospitalization rates in comparison to increased dose of ICS+LABA for 12 months
  • Spiriva Respimat (tiotropium bromide) is a 1.25mcg long term once-daily maintenance treatment of asthma for 6 years and older

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions